Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

Stock Information for Caribou Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Caribou Biosciences Inc.

Caribou Biosciences to Evaluate Strategic Alternatives
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.